EnteroBiotix, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.

Our CEO Dr James McIlroy presents at BioEquity covering the potential of our premier full-spectrum, microbiome product platform which prevents and treats disease through the restoration and enhancement of gut microbial ecology.

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

Modern Medicine publishes informative article on the clinical benefits of modulating the microbiome authored by our CEO Dr James McIlroy. In the article Dr McIlroy discusses the clinical benefits of modulating the microbiome, which are leading to new medical products and inspiring a behavioral shift in gut health.

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

EnteroBiotix today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

‘Encapsulating and Enhancing the Microbiome - A New Era for Microbe-Based Medicines’ – EnteroBiotix article features in the European Biopharmaceutical Review

EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director.

EnteroBiotix is pleased to announce that the Company has received full registration of their trademark “Number 2”. The Number 2 brand forms a core part of the Company’s strategy to control the supply chain for its Broad Spectrum Microbiota™ therapeutics.

Watch an interview with our Founder and CEO Dr. James McIlroy, where he shares our vision for mastering the microbiome to transform lives of patients.

This Boston based event is the most comprehensive forum for microbiome drug developers. Email us to arrange meeting up at the event.

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. Email us to arrange meeting up at the event.

Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome